Clinical study of a novel T-cell function assay for graft-versus-host disease (GVHD) after allogenic hematopoietic stem cell transplantation

Clinical study of a diagnostic technology using a novel T-cell function assay for graft-versus-host disease (GVHD) after allogenic hematopoietic stem cell transplantation - Clinical study of a novel T-cell function assay for graft-versus-host disease (GVHD) after allogenic hematopoietic stem cell transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046860

Enrollment

Registered

2022-02-10

Start date

2022-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancies, Aplastic Anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with hematopoietic tumor or aplastic anemia to plan allogeneic hematopoietic stem cell transplantation

Exclusion criteria

Exclusion criteria: Adults who are deemed unlikely to provide valid consent

Design outcomes

Primary

Measure	Time frame
the stimulus-responsive T cells	—

Secondary

Measure	Time frame
Severity of GVHD	—

Countries

Japan

Contacts

Public ContactHiroshi YASUI

The University of Tokyo The Institute of Medical Science

hiroyasu@ims.u-tokyo.ac.jp0334438111

Outcome results